Recombinant Human IL-1 RII Fc Chimera Protein, CF Summary
Approximately 0.3-1.8 μg/mL of Recombinant Human (rh) IL‑1 RII Fc Chimera will inhibit 50% of the biological response due to 50 pg/mL of rhIL-1 beta.
|Human IL-1 RII
(His21 - Glu343)
Accession # P27930
(Pro100 - Lys330)
Complete Your Research
Complete Your Experiment
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Background: IL-1 RII
IL-1 Receptor II (also IL‑1 R2) is a 60 ‑ 70 kDa member of the interleukin‑1 receptor family of proteins (1 ‑ 4). It serves as a non‑signaling ligand‑binding decoy receptor for IL‑1 beta and IL‑1 alpha (4). IL‑1 binds to a cell surface complex composed of IL‑1 RI and IL‑1 RAcP. Upon activation, this complex recruits MyD88 for downstream signaling (4, 5). The proinflammatory action of IL-1 is antagonized by IL‑1ra which binds to IL‑1 RI but does not initiate signaling. A second natural antagonist is IL‑1 RII, a cell surface receptor that binds both IL‑1 alpha and beta, but not IL‑1ra. IL‑1 RII is found on astrocytes, neutrophils, anterior pituitary acidophils that secrete GH, corneal epithelium, testicular Leydig and Sertoli cells, B cells and monocytes/macrophages (6 ‑ 12). Mature human IL‑1 RII is a 385 amino acid (aa) type I transmembrane glycoprotein that contains a 330 aa extracellular region with three Ig‑like domains (aa 14 ‑ 343), a 26 aa transmembrane segment, and a 29 aa cytoplasmic domain with no signaling motifs (13). There is one soluble 55 ‑ 60 kDa alternative splice form that shows a premature truncation after Gln296 (14). ARTS‑1 mediated cleavage of IL-1 RII generates a 47 kDa isoform, while alpha ‑secretase cleavage after Arg338 creates a 50 ‑ 55 kDa isoform that undergoes further processing back to Pro314 (15, 16). Human IL‑1 RII shares 59% aa identity with mouse IL‑1 RII in the extracellular region. Different forms of human IL‑1 RII demonstrate differing binding affinities for IL‑1. IL‑1 RII has a preference for IL‑1 beta over IL‑1 alpha, and binding requires the presence of IL‑1 RAcP. This interaction prevents the association of IL‑1 with IL‑1 RI and also restricts IL‑1 R to a non‑signaling receptor complex (11, 17 ‑ 19). The membrane IL‑1 RII:IL‑1 RAcP complex does not form a functional bond with IL‑1ra, and cannot bind pro‑IL‑1 beta (11, 13, 19, 20). Soluble IL‑1 RII, by contrast, demonstrates a different binding profile. Notably, it will bind pro‑IL‑1 beta rendering it unavailable for activation by extracellular proteases (19, 20). Although it will sequester both IL‑1 beta and IL‑1 alpha, its interaction with soluble IL‑1 RAcP creates a circulating high affinity complex for both IL‑1 beta and IL‑1 alpha, thus potentiating its anti‑inflammatory activity.
- Dinarello, C.A. (2011) Blood 117:3720.
- Boraschi, D. and A. Tagliabue (2006) Vitam. Horm. 74:229.
- Dunne, A. and L.A.J. O’Neill (2003) Sci STKE. Feb 25;2003(171):re3.
- Dinarello, C.A. (2009) Annu. Rev. Immunol. 27:519.
- O’Neill, L.A.J. (2008) Immunol. Rev. 226:10.
- Pousset, F. et al. (2001) J. Neurochem. 79:726.
- Bourke, E. et al. (2003) J. Immunol. 170:5999.
- French, R.A. et al. (1996) Endocrinology 137:4027.
- Cubitt, C.L. et al. (2001) Invest. Ophthalmol. Vis. Sci. 42:701.
- Gomez, E. et al. (1997) Biol. Reprod. 56:1513.
- Lang, D. et al. (1998) J. Immunol. 161:6871.
- Mantovani, A. et al. (2001) Trends Immunol. 22:328.
- McMahan, C.J. et al. (1991) EMBO J. 10:2821.
- Liu, C. et al. (1996) J. Biol. Chem. 271:20965.
- Cui, X. et al. (2003) J. Immunol. 171:6814.
- Kuhn, P-H. et al. (2007) J. Biol. Chem. 282:11982.
- Smith, D.E. et al. (2003) Immunity 18:87.
- Makinowsky, D. et al. (1998) FEBS Lett. 429:299.
- Neumann, D. et al. (2000) J. Immunol. 165:3350.
- Symons, J. A. et al. (1995) Proc. Natl. Acad. Sci. USA 92:1714.
- Wang, D. et al. (2010) Nat. Immunol. 11:905.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human IL-1 RII Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human IL-1 RII Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human IL-1 RII Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image